- |||||||||| Review, Journal: Novel agents for relapsed and refractory follicular lymphoma. (Pubmed Central) - Jun 22, 2019
Combination studies are currently underway with novel-novel combinations and with traditional chemotherapy regimens. This overview will discuss the results of several recent studies exploring activity of novel drugs in relapsed follicular lymphoma.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal, IO biomarker: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. (Pubmed Central) - Jun 22, 2019 P3 Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. (Funded by F. Hoffmann-La Roche and AbbVie; ClinicalTrials.gov number, NCT02242942.).
- |||||||||| Gazyva (obinutuzumab) / Biogen, Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme Therapeutics
Review, Journal: A tale of two antibodies: obinutuzumab versus rituximab. (Pubmed Central) - Jun 15, 2019 The benefit conferred by obinutuzumab over rituximab may be context-specific and vary based on histological subtype and immune integrity. This comprehensive review will explore the preclinical differences, investigate the proposed pathogenesis of rituximab resistance, compare the employed dosing strategies and interrogate available clinical results to help inform practice.
- |||||||||| Gazyva (obinutuzumab) / Biogen, Roche, Rituxan (rituximab) / Roche, Biogen
Clinical, Journal: Management of patients with follicular lymphoma treated first line with obinutuzumab. (Pubmed Central) - Jun 6, 2019 As median overall survival approaches 20 years or more, the long-term effects and sequencing of any strategy should be considered. Here we discuss the considerations for selection of front-line therapy, based on evidence and local Australian clinician experience, in the management of first line follicular lymphoma.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial suspension: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 3, 2019 P1, N=60, Suspended, Here we discuss the considerations for selection of front-line therapy, based on evidence and local Australian clinician experience, in the management of first line follicular lymphoma. Recruiting --> Suspended
- |||||||||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: GO29834: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - May 28, 2019 P1, N=128, Recruiting, Trial primary completion date: Dec 2021 --> Jul 2019 Trial primary completion date: Feb 2022 --> Aug 2019
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open, Trial primary completion date: OLYMP-1: Obinutuzumab in Marginal Zone Lymphoma (clinicaltrials.gov) - May 20, 2019 P2, N=56, Recruiting, N=25 --> 34 Not yet recruiting --> Recruiting | Trial primary completion date: May 2019 --> Oct 2019
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion, Trial completion date: Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients (clinicaltrials.gov) - May 8, 2019 P2, N=66, Completed, In contrast to [F]FDG PET, immunoPET provides not only information about the extent of disease but also about presence and localisation of the therapeutic target. Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Mar 2019
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
Clinical, P2 data, Journal: Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. (Pubmed Central) - May 7, 2019 P2 The high proportion of patients who achieved overall responses, both treatment-naive and relapsed or refractory patients irrespective of physical fitness and genetic risk factors, compare favourably to established chronic lymphocytic leukaemia therapies. Further follow-up will help to define whether the remissions with eradication of minimal residual disease achieved with this combination are durable after treatment discontinuation.
|